BIOMARKER PANELS, DIAGNOSTIC METHODS AND TEST KITS FOR OVARIAN CANCER

摘要

Methods are provided for predicting the presence, subtype and stage of ovarian cancer, as well as for assessing the therapeutic efficacy of a cancer treatment and determining whether a subject potentially is developing cancer. Associated test kits, computer and analytical systems as well as software and diagnostic models are also provided.

主权项

1. A method of determining the ovarian cancer status of a subject, comprising the steps of:
measuring the level of CA-125, HE4 and one or more biomarkers selected from the group consisting of IL-2 receptor alpha (IL-2Ra), Alpha-1-Antitrypsin (AAT), C-Reactive Protein (CRP), YKL-40, Cellular Fibronectin (cFib), prostasin, Tissue Inhibitor of Metalloproteinases 1 (TIMP-1), IL-8, IL-6, Vascular Endothelial Growth Factor B (VEGF-B), Matrix Metalloproteinase-7 (MMP-7), calprotectin, Insulin-like Growth Factor-Binding Protein 2 (IGFBP-2), Lectin-Like Oxidized LDL Receptor 1 (LOX-1), neuropilin-1, TNFR2, and MPIF-1 in a biological sample obtained from the subject; and correlating the measurements with ovarian cancer status.